Compare Biocon Ltd with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs TTK HEALTHCARE - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON TTK HEALTHCARE BIOCON /
TTK HEALTHCARE
 
P/E (TTM) x 31.5 25.2 125.0% View Chart
P/BV x 4.1 1.7 240.4% View Chart
Dividend Yield % 0.2 0.9 26.5%  

Financials

 BIOCON    TTK HEALTHCARE
EQUITY SHARE DATA
    BIOCON
Mar-19
TTK HEALTHCARE
Mar-19
BIOCON /
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs7071,215 58.2%   
Low Rs554610 90.8%   
Sales per share (Unadj.) Rs91.9444.4 20.7%  
Earnings per share (Unadj.) Rs16.717.2 96.9%  
Cash flow per share (Unadj.) Rs24.227.6 87.5%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.20.5 28.9%  
Book value per share (Unadj.) Rs101.6177.9 57.1%  
Shares outstanding (eoy) m600.0014.13 4,246.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.92.1 334.1%   
Avg P/E ratio x37.752.9 71.3%  
P/CF ratio (eoy) x26.133.0 79.0%  
Price / Book Value ratio x6.25.1 121.0%  
Dividend payout %6.029.0 20.6%   
Avg Mkt Cap Rs m378,33012,894 2,934.1%   
No. of employees `0006.12.3 265.2%   
Total wages/salary Rs m11,6531,307 891.6%   
Avg. sales/employee Rs Th8,994.32,715.7 331.2%   
Avg. wages/employee Rs Th1,900.7565.3 336.2%   
Avg. net profit/employee Rs Th1,635.3105.4 1,551.4%   
INCOME DATA
Net Sales Rs m55,1446,279 878.3%  
Other income Rs m1,44478 1,863.2%   
Total revenues Rs m56,5886,356 890.3%   
Gross profit Rs m15,883496 3,204.8%  
Depreciation Rs m4,478147 3,052.5%   
Interest Rs m70934 2,097.6%   
Profit before tax Rs m12,140393 3,092.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123149 1,425.8%   
Profit after tax Rs m10,026244 4,114.1%  
Gross profit margin %28.87.9 364.9%  
Effective tax rate %17.537.9 46.1%   
Net profit margin %18.23.9 468.4%  
BALANCE SHEET DATA
Current assets Rs m48,2282,717 1,774.9%   
Current liabilities Rs m30,3761,571 1,933.8%   
Net working cap to sales %32.418.3 177.3%  
Current ratio x1.61.7 91.8%  
Inventory Days Days6832 212.4%  
Debtors Days Days8647 183.3%  
Net fixed assets Rs m64,130991 6,471.2%   
Share capital Rs m3,000141 2,123.1%   
"Free" reserves Rs m57,9802,373 2,443.3%   
Net worth Rs m60,9802,514 2,425.3%   
Long term debt Rs m15,7663 463,705.9%   
Total assets Rs m121,9244,158 2,932.2%  
Interest coverage x18.112.6 143.7%   
Debt to equity ratio x0.30 19,119.3%  
Sales to assets ratio x0.51.5 30.0%   
Return on assets %8.86.7 131.9%  
Return on equity %16.49.7 169.6%  
Return on capital %16.816.9 98.9%  
Exports to sales %28.13.6 784.0%   
Imports to sales %18.90.5 3,825.7%   
Exports (fob) Rs m15,506225 6,885.4%   
Imports (cif) Rs m10,39931 33,599.4%   
Fx inflow Rs m15,506225 6,885.4%   
Fx outflow Rs m10,39971 14,623.8%   
Net fx Rs m5,107154 3,314.3%   
CASH FLOW
From Operations Rs m11,546173 6,670.1%  
From Investments Rs m-7,13897 -7,396.9%  
From Financial Activity Rs m-2,417-307 786.5%  
Net Cashflow Rs m2,103-38 -5,578.2%  

Share Holding

Indian Promoters % 40.4 65.4 61.8%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 3.7 227.0%  
FIIs % 10.7 5.2 205.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 25.8 77.1%  
Shareholders   109,995 12,723 864.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NATCO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 142 Points Higher; Healthcare and Capital Goods Stocks Witness Buying(Closing)

Extending gains to the third straight day, Indian share markets witnessed buying interest throughout the day today, amid sustained foreign fund inflows and positive cues from global markets.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (3QFY20); Net Profit Down 8.3% (Quarterly Result Update)

Jan 30, 2020 | Updated on Jan 30, 2020

For the quarter ended December 2019, TTK HEALTHCARE has posted a net profit of Rs 45 m (down 8.3% YoY). Sales on the other hand came in at Rs 2 bn (up 11.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Stocks at 50% Off(Fast Profits Daily)

Aug 7, 2020

In this video I'll show you how to enter into a long trade at the right price.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Aug 10, 2020 (Close)

TRACK BIOCON

BIOCON - AUROBINDO PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS